Amphastar Pharmaceuticals (FRA:29A) Interest Expense : €-32.8 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Amphastar Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Amphastar Pharmaceuticals's interest expense for the three months ended in Mar. 2024 was € -7.9 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was €-32.8 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Amphastar Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was € 44.2 Mil. Amphastar Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was € -7.9 Mil. Amphastar Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 was 5.58. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Amphastar Pharmaceuticals Interest Expense Historical Data

The historical data trend for Amphastar Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amphastar Pharmaceuticals Interest Expense Chart

Amphastar Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.11

-0.31

-0.78

-1.74

-24.90

Amphastar Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.37	-3.33	-12.84	-8.67	-7.92

Amphastar Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-32.8 Mil.

Amphastar Pharmaceuticals (FRA:29A) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Amphastar Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was €-7.9 Mil. Its Operating Income for the three months ended in Mar. 2024 was €44.2 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was €572.9 Mil.

Amphastar Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	44.169	/	-7.922
	=	5.58

The higher the ratio, the stronger the company's financial strength is.

Amphastar Pharmaceuticals (FRA:29A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (FRA:29A) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

AMPH:USA 29A:Germany

Address

11570 6th Street, Rancho Cucamonga, CA, USA, 91730

Website

http://www.amphastar.com

Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Amphastar Pharmaceuticals (FRA:29A) Headlines

No Headlines